Pharvaris (PHVS) Stock Price Target 2026

The average analyst price target for Pharvaris is $51.22, 55.3% above the current price. Of 15 analysts, 15 rate it Buy. Targets range from $25 to $79. The latest change came on Oct 23, 2026, when B of A Securities upgraded Pharvaris from Neutral to Buy with a $44 price target.

The Average Analyst Price Target for Pharvaris is $51.22.

Price Target Range — 12 Quarters

Analyst Consensus — 15 Analysts

3S.Buy

12Buy

Consensus RatingOutperform# Analysts15Avg. Consensus PT$51.22Upside to Avg. PT+55.3%

Rating Trend — Last 9 Months

Latest Upgrades and Downgrades for Pharvaris Stock

See all ratings →

Date	Firm	Analyst	Action	Rating Change	Price Target
Oct 23, 2026	B of A Securities	Tazeen Ahmad	Upgrade	Neutral→Buy	$44
Sep 10, 2026	Guggenheim	Debjit Chattopadhyay	PT Raise	Buy	$40→$44
Sep 9, 2026	Morgan Stanley	Maxwell Skor	PT Raise	Overweight	$46→$62
Sep 9, 2026	Leerink Partners	Joseph Schwartz	PT Raise	Outperform	$50→$65
Sep 9, 2026	Wells Fargo	Yanan Zhu	PT Raise	Overweight	$55→$65
Sep 9, 2026	RBC Capital	Nevin Varghese	PT Raise	Outperform	$52→$62
Sep 9, 2026	Citizens	Jonathan Wolleben	PT Raise	Market Outperform	$75→$79
Sep 9, 2026	Wedbush	Laura Chico	PT Raise	Outperform	$42→$50
Sep 8, 2026	HC Wainwright & Co.	Patrick R. Trucchio	Maintained	Buy	$60
Sep 8, 2026	Wedbush	Laura Chico	Maintained	Outperform	$42
Aug 13, 2026	RBC Capital	Brian Abrahams	PT Raise	Outperform	$51→$52
Aug 13, 2026	Guggenheim	Debjit Chattopadhyay	PT Raise	Buy	$39→$40
Aug 13, 2026	Citizens	Jonathan Wolleben	PT Raise	Market Outperform	$74→$75
Jul 15, 2026	Wells Fargo	Yanan Zhu	Initiate	Overweight	$55
Jun 25, 2026	Morgan Stanley	Maxwell Skor	PT Raise	Overweight	$41→$46
May 13, 2026	Citizens	Jonathan Wolleben	PT Cut	Market Outperform	$75→$74
Apr 9, 2026	Wolfe Research	Andy Chen	Initiate	Outperform	$42
Apr 7, 2026	Wedbush	Laura Chico	PT Raise	Outperform	$41→$42
Apr 6, 2026	RBC Capital	Brian Abrahams	PT Cut	Outperform	$52→$51
Mar 9, 2026	RBC Capital	Brian Abrahams	Initiate	Outperform	$52